about
Nerve growth factor downregulates inflammatory response in human monocytes through TrkAWolman disease associated with hemophagocytic lymphohistiocytosis: attempts for an explanation.Inflammasome activation by cystine crystals: implications for the pathogenesis of cystinosis.Deregulation of the IL-1β axis in chronic recurrent multifocal osteomyelitis.Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis.An international registry on autoinflammatory diseases: the Eurofever experience.Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritisMechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans.IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases.Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis.A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study.Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation.Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanerceptMacrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome.The impact of chronic inflammation on the growing skeleton: lessons from interleukin-6 transgenic mice.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Coll2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation CollIntra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial.Macrophage activation syndrome in the era of biologic therapy.Inflammatory events during food protein-induced enterocolitis syndrome reactions.Development of the autoinflammatory disease damage index (ADDI).NGF and Its Receptors in the Regulation of Inflammatory Response.Biologic therapy modifies clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis.Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis.Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.Kikuchi-Fujimoto disease in patient with systemic phacomatosis pigmentovascularis.Acute rheumatic fever with chorea.A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis.Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis.Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis.Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade.Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice.ProNGF-p75NTR axis plays a proinflammatory role in inflamed joints: a novel pathogenic mechanism in chronic arthritis.Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy.Stimulating effect of growth hormone on cytokine release in children.Serum cytokine levels in GH-deficient children during substitutive GH therapy.Cronic non-bacterial osteomyelitis (CNO) in a cohort of pediatric patients: clinical, biological and radiological response to treatment with Anakinra.
P50
Q28308171-863AC16B-0F88-4CCA-8DD9-7CB5C390DEA3Q33415410-FB048A8C-6D3B-4B89-9A67-A81EFFB1328EQ33660585-A7550BD8-89B0-409F-80F0-AD986E6EB4B1Q33945041-AFFBFD30-9811-475B-BE06-7EC20D8BD4D8Q34196828-1F928874-4AD6-48EB-9D9C-7186FFD0DD21Q34257724-313AC064-9E96-4EAF-9656-1F8166DD6023Q34274249-249995FC-9C6C-47F1-86E5-02FC389D0399Q35148782-A48A335B-7BE7-4A50-B6DB-23FF8AFD4F7DQ35291353-D10877F1-341D-44BE-B7AB-45CD6FA519E9Q35605487-3DE8C215-3684-4A30-B0B3-A9720F4C1B58Q36517235-16CC7E1D-2E25-4F43-A9AC-EA689911ACD8Q36655896-F1C1B103-2A69-453A-8BA2-93A8BC797D41Q37361075-A8EAC26C-A0FF-44EB-B528-261202FED1CDQ37515104-CC416ECC-128C-46B6-AC55-491F329A74E4Q37518319-EDF43376-FB65-428D-8213-A745C2EACAF9Q37589316-A76DBC3C-A162-4FCE-925F-0E2F0D38E3BCQ37639019-7C00C70D-5DB0-413B-977C-BCCC9ABDB3A9Q38093452-32DCC21A-860B-4DEC-8F20-281D707388BCQ38575277-F5D20F97-F594-4650-BAEB-B2CFFE0FA84FQ38729149-5F1B7412-0C18-40C4-9B61-A39DD24763C6Q38761381-52CD0918-E4E1-4552-8E2D-19DE7FE7D773Q38786756-F333F172-B428-4151-B4F2-4BB33E34E5EEQ38856117-2CE747ED-DB65-4723-BC93-A7DE87FAD18DQ38997969-E7401664-3B2E-423A-A192-232466A70F72Q39297792-1562A7D8-0CE8-40AF-A8D3-6D1CC1737D1FQ39302854-881E32C6-FECF-4803-A046-B1C6EEAEDA79Q39455067-F5AE90E2-7F13-49A5-8691-2B5CDE07DDB0Q39761819-87AD552C-BDD3-4E35-BA0C-EDBB6E64E842Q40189731-6DD122C5-A30B-4D9F-91B7-E74DA7908D06Q40266921-46FCA2E2-A0BE-4163-BF19-82066BAD0268Q40555458-84336E04-0FF3-40AF-BD72-9F6BD75754D0Q40626780-420B51E8-2B13-4D22-B2B4-6378DD131640Q40700680-107642B7-E2F7-41DC-9112-A57B880624C1Q40773636-9C8BF6B2-6380-467B-8139-FC4038701487Q41045084-E883B4D8-EB9B-41E2-9F0A-3BC8D1EC4237Q41687143-B67F50BB-4948-452E-9ACB-37ED9DA50EB6Q42133691-E5E6F5B1-1D20-47BA-8B59-57DAFDAB6A55Q42451978-A06D7DF2-F1CC-4807-86B9-08CE85E46292Q42475035-1471FD9B-396E-4616-B56F-81CC90A1D2E9Q46286222-19A7545B-183A-46EC-9E76-09EB715A7FD6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fabrizio De Benedetti
@ast
Fabrizio De Benedetti
@en
Fabrizio De Benedetti
@es
Fabrizio De Benedetti
@nl
Fabrizio De Benedetti
@sl
type
label
Fabrizio De Benedetti
@ast
Fabrizio De Benedetti
@en
Fabrizio De Benedetti
@es
Fabrizio De Benedetti
@nl
Fabrizio De Benedetti
@sl
prefLabel
Fabrizio De Benedetti
@ast
Fabrizio De Benedetti
@en
Fabrizio De Benedetti
@es
Fabrizio De Benedetti
@nl
Fabrizio De Benedetti
@sl
P106
P1153
7005444704
P31
P496
0000-0001-8749-8232